Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $3.31 billion. The enterprise value is $2.62 billion.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
Earnings Date | May 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AKRO has 79.68 million shares outstanding. The number of shares has increased by 29.31% in one year.
Current Share Class | 79.68M |
Shares Outstanding | 79.68M |
Shares Change (YoY) | +29.31% |
Shares Change (QoQ) | +11.45% |
Owned by Insiders (%) | 1.32% |
Owned by Institutions (%) | 81.43% |
Float | 66.53M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.01 |
P/TBV Ratio | 3.05 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.80
Current Ratio | 16.80 |
Quick Ratio | 16.17 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -63.41 |
Financial Efficiency
Return on equity (ROE) is -27.92% and return on invested capital (ROIC) is -19.48%.
Return on Equity (ROE) | -27.92% |
Return on Assets (ROA) | -18.52% |
Return on Invested Capital (ROIC) | -19.48% |
Return on Capital Employed (ROCE) | -27.51% |
Revenue Per Employee | n/a |
Profits Per Employee | -$4.28M |
Employee Count | 63 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +111.35% in the last 52 weeks. The beta is -0.13, so AKRO's price volatility has been lower than the market average.
Beta (5Y) | -0.13 |
52-Week Price Change | +111.35% |
50-Day Moving Average | 41.66 |
200-Day Moving Average | 34.41 |
Relative Strength Index (RSI) | 49.91 |
Average Volume (20 Days) | 1,174,540 |
Short Selling Information
The latest short interest is 6.78 million, so 8.51% of the outstanding shares have been sold short.
Short Interest | 6.78M |
Short Previous Month | 6.31M |
Short % of Shares Out | 8.51% |
Short % of Float | 10.20% |
Short Ratio (days to cover) | 5.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -306.35M |
Pretax Income | -204.18M |
Net Income | -269.44M |
EBITDA | -306.33M |
EBIT | -306.35M |
Earnings Per Share (EPS) | -$3.74 |
Full Income Statement Balance Sheet
The company has $686.29 million in cash and n/a in debt, giving a net cash position of $686.29 million or $8.61 per share.
Cash & Cash Equivalents | 686.29M |
Total Debt | n/a |
Net Cash | 686.29M |
Net Cash Per Share | $8.61 |
Equity (Book Value) | 1.08B |
Book Value Per Share | 13.78 |
Working Capital | 670.71M |
Full Balance Sheet Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |